Related Experiment Video
Updated: Jun 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Virological relapse in chronic hepatitis C
F Fred Poordad1, Steven L Flamm
1Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Fred.Poordad@cshs.org
Abstract:
Approximately one-third of all patients infected with hepatitis C virus (HCV) genotype 1 who complete pegylated interferon alpha based therapy and have undetectable serum HCV RNA at the end of treatment will experience relapse. Although relapse is a common outcome of therapy, its pathology and strategies for optimal management are poorly understood; however, optimized ribavirin dosing is recognized as pivotal in mitigating relapse. Recent data also suggest that early viral kinetics might help identify particular patient groups, such as slow responders, who are predisposed to relapse. This review provides a comprehensive overview of the importance of relapse in patients with chronic hepatitis C, including its underlying pathobiology, potential predictors and strategies to optimize the retreatment of previous relapsers.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Cytomegalovirus Disease
Size and Structure of Viral Genomes
Retroviruses
